✦ LIBER ✦

Clinical aspects of a phase I trial of 5,6-dimethylxanthenone-4-acetic acid (DMXAA), a novel antivascular agent

✍ Scribed by Jameson, M B; Thompson, P I; Baguley, B C; Evans, B D; Harvey, V J; Porter, D J; McCrystal, M R; Small, M; Bellenger, K; Gumbrell, L

Book ID: 109997600
Publisher: Nature Publishing Group
Year: 2003
Tongue: English
Weight: 122 KB
Volume: 88
Category: Article
ISSN: 0007-0920
DOI: 10.1038/sj.bjc.6600992

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

5,6-Dimethylxanthenone-4-acetic acid (DM

5,6-Dimethylxanthenone-4-acetic acid (DMXAA), a novel antivascular agent: phase I clinical and pharmacokinetic study

✍ Rustin, G J S; Bradley, C; Galbraith, S; Stratford, M; Loadman, P; Waller, S; Be 📂 Article 📅 2003 🏛 Nature Publishing Group 🌐 English ⚖ 149 KB

Pharmacokinetics of 5,6-dimethylxantheno

Pharmacokinetics of 5,6-dimethylxanthenone-4-acetic acid (AS1404), a novel vascular disrupting agent, in phase I clinical trial

✍ M. B. Jameson; B. C. Baguley; P. Kestell; L. Zhao; J. W. Paxton; P. I. Thompson; 📂 Article 📅 2006 🏛 Springer 🌐 English ⚖ 336 KB

An Improved Synthesis of 5,6-Dimethylxan

An Improved Synthesis of 5,6-Dimethylxanthenone-4-acetic Acid (DMXAA).

✍ Graham J. Atwell; Shangjin Yang; William A. Denny 📂 Article 📅 2003 🏛 John Wiley and Sons ⚖ 119 KB

## Abstract For Abstract see ChemInform Abstract in Full Text.

Marked potentiation of the antitumour ac

Marked potentiation of the antitumour activity of chemotherapeutic drugs by the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA)

✍ Bronwyn G. Siim; Alan E. Lee; Sahar Shalal-Zwain; Frederik B. Pruijn; Mark J. Mc 📂 Article 📅 2003 🏛 Springer 🌐 English ⚖ 343 KB

A new short synthesis of 5,6-dimethylxan

A new short synthesis of 5,6-dimethylxanthenone-4-acetic acid (ASA404, DMXAA)

✍ Shangjin Yang; William A. Denny 📂 Article 📅 2009 🏛 Elsevier Science 🌐 French ⚖ 217 KB

A new short synthesis of 5,6-dimethylxanthenone-4-acetic acid (ASA404) is developed. The key steps of the synthesis are dibromination of 3,4-dimethylbenzoic acid, followed by regioselective coupling with 2hydroxyphenylacetic acid and subsequent cyclodehydration.

Phase I clinical trial and human pharmac

Phase I clinical trial and human pharmacokinetics of 2,4-diamino-5-adamantyl-6-methyl pyrimidine ethane sulfonate (DAMP-ES): a lipid-soluble antifolate

✍ Patrick J. Creaven; Sigmund F. Zakrzewski; William R. Greco; Stefan Madajewicz; 📂 Article 📅 1988 🏛 Springer 🌐 English ⚖ 641 KB